Tags

Type your tag names separated by a space and hit enter

Tracking resistance among bacterial respiratory tract pathogens: summary of findings of the TRUST Surveillance Initiative, 2001-2005.
Postgrad Med. 2008 Sep; 120(3 Suppl 1):8-15.PM

Abstract

Antimicrobial resistance observed among common respiratory tract pathogens--Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis--may complicate empiric therapeutic selection to treat community-acquired respiratory tract infections. The Tracking Resistance in the United States Today (TRUST) study determined the in vitro activities of frequently prescribed antimicrobial agents against isolates collected from all 50 states from 2001 to 2005. For S pneumoniae (N = 27,781), susceptibility of selected agents in ascending order were penicillin (oral) (65.4%), trimethoprim-sulfamethoxazole (TMP-SMX) (69.5%), erythromycin (72.0%), cefuroxime (oral) (75.9%), tetracycline (85.3%), amoxicillinclavulanate (92.6%), ceftriaxone (nonmeningitis) (96.6%), and levofloxacin (99.0%). Susceptibility to levofloxacin, which was used as a representative of the respiratory fluoroquinolones, was near 99% from 2001 to 2005, and the minimum inhibitory concentration (90%) (MIC(90)) remained unchanged at 1 microg/mL. Levofloxacin and the other respiratory fluoroquinolones remained highly effective against penicillin-resistant S pneumoniae(PRSP) (98%-99% susceptible). However, susceptibility of PRSP to amoxicillin-clavulanate decreased from 62%S in 2003 to 48%S in 2005. Haemophilus influenzae susceptibility to ampicillin averaged near 70%, and near 75% to TMP-SMX. Susceptibility rates to levofloxacin and the other respiratory fluoroquinolones for H influenzae and M catarrhalis remained at or near 100%. Although resistance rates among S pneumoniae have stabilized for penicillin (oral) at elevated levels and increased for macrolides, susceptibility to the respiratory fluoroquinolones has consistently remained high, as they have for H influenzae and M catarrhalis.

Authors+Show Affiliations

Eurofins Medinet Inc., Herndon, VA 20171-4603, USA. daniel.sahm@eurofinsmedinet.comNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

18931466

Citation

Sahm, Daniel F., et al. "Tracking Resistance Among Bacterial Respiratory Tract Pathogens: Summary of Findings of the TRUST Surveillance Initiative, 2001-2005." Postgraduate Medicine, vol. 120, no. 3 Suppl 1, 2008, pp. 8-15.
Sahm DF, Brown NP, Draghi DC, et al. Tracking resistance among bacterial respiratory tract pathogens: summary of findings of the TRUST Surveillance Initiative, 2001-2005. Postgrad Med. 2008;120(3 Suppl 1):8-15.
Sahm, D. F., Brown, N. P., Draghi, D. C., Evangelista, A. T., Yee, Y. C., & Thornsberry, C. (2008). Tracking resistance among bacterial respiratory tract pathogens: summary of findings of the TRUST Surveillance Initiative, 2001-2005. Postgraduate Medicine, 120(3 Suppl 1), 8-15. https://doi.org/10.3810/pgm.2008.09.suppl52.279
Sahm DF, et al. Tracking Resistance Among Bacterial Respiratory Tract Pathogens: Summary of Findings of the TRUST Surveillance Initiative, 2001-2005. Postgrad Med. 2008;120(3 Suppl 1):8-15. PubMed PMID: 18931466.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Tracking resistance among bacterial respiratory tract pathogens: summary of findings of the TRUST Surveillance Initiative, 2001-2005. AU - Sahm,Daniel F, AU - Brown,Nina P, AU - Draghi,Deborah C, AU - Evangelista,Alan T, AU - Yee,Y Cheung, AU - Thornsberry,Clyde, PY - 2008/10/24/pubmed PY - 2008/11/19/medline PY - 2008/10/24/entrez SP - 8 EP - 15 JF - Postgraduate medicine JO - Postgrad Med VL - 120 IS - 3 Suppl 1 N2 - Antimicrobial resistance observed among common respiratory tract pathogens--Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis--may complicate empiric therapeutic selection to treat community-acquired respiratory tract infections. The Tracking Resistance in the United States Today (TRUST) study determined the in vitro activities of frequently prescribed antimicrobial agents against isolates collected from all 50 states from 2001 to 2005. For S pneumoniae (N = 27,781), susceptibility of selected agents in ascending order were penicillin (oral) (65.4%), trimethoprim-sulfamethoxazole (TMP-SMX) (69.5%), erythromycin (72.0%), cefuroxime (oral) (75.9%), tetracycline (85.3%), amoxicillinclavulanate (92.6%), ceftriaxone (nonmeningitis) (96.6%), and levofloxacin (99.0%). Susceptibility to levofloxacin, which was used as a representative of the respiratory fluoroquinolones, was near 99% from 2001 to 2005, and the minimum inhibitory concentration (90%) (MIC(90)) remained unchanged at 1 microg/mL. Levofloxacin and the other respiratory fluoroquinolones remained highly effective against penicillin-resistant S pneumoniae(PRSP) (98%-99% susceptible). However, susceptibility of PRSP to amoxicillin-clavulanate decreased from 62%S in 2003 to 48%S in 2005. Haemophilus influenzae susceptibility to ampicillin averaged near 70%, and near 75% to TMP-SMX. Susceptibility rates to levofloxacin and the other respiratory fluoroquinolones for H influenzae and M catarrhalis remained at or near 100%. Although resistance rates among S pneumoniae have stabilized for penicillin (oral) at elevated levels and increased for macrolides, susceptibility to the respiratory fluoroquinolones has consistently remained high, as they have for H influenzae and M catarrhalis. SN - 1941-9260 UR - https://www.unboundmedicine.com/medline/citation/18931466/Tracking_resistance_among_bacterial_respiratory_tract_pathogens:_summary_of_findings_of_the_TRUST_Surveillance_Initiative_2001_2005_ L2 - https://www.tandfonline.com/doi/full/10.3810/pgm.2008.09.suppl52.279 DB - PRIME DP - Unbound Medicine ER -